Uwe Fraass

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Ejection Fraction

Peritoneal Dialysis

Clinical Practice

Top Venues

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Michael Lehrke, Anja Vogt, Volker J J Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N Dhalwani, Kausik K Ray
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Advances in therapy 41 (3) (2024)
Michael Lehrke, Anja Vogt, Volker J J Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N Dhalwani, Kausik K Ray
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Advances in therapy 41 (3) (2024)
Michael Lehrke, Anja Vogt, Volker J J Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N Dhalwani, Kausik K Ray
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Advances in therapy 41 (3) (2024)
Michael Lehrke, Anja Vogt, Volker J J Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N Dhalwani, Kausik K Ray
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Advances in therapy 41 (3) (2024)
Michael Lehrke, Anja Vogt, Volker J J Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N Dhalwani, Kausik K Ray
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Advances in therapy (2024)
Michael Lehrke, Anja Vogt, Volker J J Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N Dhalwani, Kausik K Ray
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Advances in therapy 41 (3) (2024)